Skip to main content
. 2020 Oct 27;12(10):792–806. doi: 10.4254/wjh.v12.i10.792

Table 1.

Clinical and demographic characteristics of nonalcoholic fatty liver disease patients and controls

Variables
NAFLD, n = 148
Controls, n = 137
P value
Female 111 (75.0%) 97 (70.8%) 0.426
Age (yr) 57 (46.3-63) 55 (43 61.5) 0.610
BMI (kg/m2) 32.8 ± 4.8 25.4 ± 3.3 < 0.0001
Hypertension 98 (66.2%) 24 (17.5%) < 0.0001
Diabetes mellitus 69 (46.6%) 12 (8.8%) < 0.0001
Dyslipidemia 108 (73.0%) 19 (13.5%) < 0.0001
Fasting glucose (mg/dL) 101 (90-124.8) 88 (83-98) < 0.0001
AST (U/L) 34 (25.5-56.5) 24 (20.3-29) < 0.0001
ALT (U/L) 38 (28-70.5) 29.5 (23-38) < 0.0001
GGT (U/L) 53 (29-116) 28 (18.5-55.5) < 0.0001
ALP (U/L) 97 (74-116.8) 75 (58.3-83.8) < 0.0001
Total bilirubin (mg/dL) 0.6 (0.5-0.9) 0.7 (0.5-0.8) 0.438
Triglycerides (mg/dL) 162.5 (110-205.3) 126.5 (93-176) 0.006
Total cholesterol (mg/dL) 195.8 ± 41.5 179.9 ± 47.1 0.006
VLDL (mg/dL) 32 (22-42.3) 24.5 (17.3-33.8) 0.001
HDL (mg/dL) 48 (39.5-54) 47 (40.5-60.8) 0.404
LDL (mg/dL) 107.5 (89.5-137.9) 96 (67.8-117.5) 0.009
Platelets (109/L) 219.4 ± 81.8 254.6 ± 82.4 0.439
Ferritin (ng/mL) 89 (42.7-168.5) 32 (32-32) 0.349
D vitamin (ng/mL) 22 (19-27.7) 26.95 (20.5-32.5) 0.139

The data are expressed as n (%), or as mean ± SD for normally distributed variables and as median (interquartile range) when distribution of the variable was skewed. NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; AST: Serum aspartate aminotransferase; VLDL: Very low-density lipoprotein; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; LDL: Low-density lipoprotein cholesterol.